RTTNews | Sep 13, 2021 12:46PM EDT

12:46 Monday, September 13, 2021 (RTTNews.com) - Shares of aTyr Pharma, Inc. (LIFE) are gaining nearly 40% on Monday after the clinical-stage biotherapeutics company and its Hong Kong Subsidiary, Pangu BioPharma, announced positive data from a phase 1b/2a clinical trial demonstrating consistent dose response of ATYR1923 in pulmonary sarcoidosis.

LIFE is currently trading at $7.56, up $2.08 or 38.03%, on the Nasdaq, on a volume of 39.7 million shares, far above the average volume of 181 thousand. The stock has traded between $2.93 to $8.33 per share in the past 52-week period. The stock's value has more than doubled in that time frame.

According to the company, ATYR1923 was safe and well-tolerated at all doses with no drug-related serious adverse events or signal of immunogenicity.

Pulmonary sarcoidosis is an inflammatory disease characterized by the formulation of granulomas, clumps of inflammatory cells, in one or more organs of the body. Approximately 200,000 Americans live with pulmonary sarcoidosis.

Read the original article on RTTNews ( https://www.rttnews.com/3225243/atyr-pharma-surges-40-on-positive-data-from-pulmonary-sarcoidosis-drug-trial.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved